1. In this randomized-controlled trial, two 12-day courses of teplizumab improved C-peptide levels compared to placebo at week 78 in patients with stage three type 1 diabetes. 2. No significant differences were observed between the teplizumab and placebo groups with respect to secondary clinical outcomes, including clinically relevant hypoglycemic events. Evidence Rating Level: 1 (Excellent) Study
The Veterinary Microbiology and Pathology department at WSU held an “Advances in Immunology Seminar” presented by Dr. Michelle Massaquoi Jan. 11, with the purpose of discussing the mechanisms of a bacterial protein known as the Befa cell. Massaquo is a PhD Scientist who earned her Doctorate in Molecular Biology at the University of Oregon, where.
Welcome to the 2 Minute Medicine Podcast, summarizing the latest medical studies, curated and written by practicing physicians. On this podcast, twice a month, we cover the latest in healthcare news and research evidence. Our episode is live! Episode Description In this episode, we begin by discussing our article of the week which comes from
1. In this randomized controlled trial, the Janus kinase (JAK) inhibitor baricitinib was associated with preserved β-cell function compared to placebo in patients with new-onset type 1 diabetes mellitus (T1DM). 2. Patients receiving baricitinib also demonstrated tighter glycemic control compared to placebo. Evidence Rating Level: 1 (Excellent) Study Rundown: The mainstay of T1DM treatment is